Prescient Imaging

Executive Summary

Prescient Imaging, founded in 2018 and based in San Francisco, is a medical technology company pioneering portable PET imaging. Its first FDA-cleared product, the BBX-PET, is a compact scanner designed for breast, brain, and extremity imaging at the point of care. By making advanced diagnostic tools more accessible to specialty practices, Prescient Imaging aims to expand the reach of molecular imaging beyond traditional hospital settings, improving early detection of diseases like cancer and neurological disorders. As a private company with a cleared product, Prescient Imaging is now focused on commercial adoption and scaling. The portable PET market is nascent but growing, driven by demand for decentralized imaging. Key challenges include proving clinical utility, building sales channels, and securing reimbursement. With its novel technology and first-mover advantage, Prescient Imaging is well-positioned to capture a niche in point-of-care diagnostics, though execution risk remains.

Upcoming Catalysts (preview)

• Q4 2026Initial commercial sales of BBX-PET to specialty clinics70% success
• Q2 2027FDA 510(k) clearance for additional imaging applications (e.g., cardiac or pediatric)50% success
• TBDSeries A or B funding round for manufacturing scale-up65% success